0001562180-23-008590.txt : 20231229
0001562180-23-008590.hdr.sgml : 20231229
20231229182520
ACCESSION NUMBER: 0001562180-23-008590
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231229
FILED AS OF DATE: 20231229
DATE AS OF CHANGE: 20231229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Antonijevic Irina
CENTRAL INDEX KEY: 0001926476
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41477
FILM NUMBER: 231528998
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Ltd.
CENTRAL INDEX KEY: 0001935979
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
FORMER COMPANY:
FORMER CONFORMED NAME: Biohaven Research Ltd.
DATE OF NAME CHANGE: 20220629
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2023-12-29
false
0001935979
Biohaven Ltd.
BHVN
0001926476
Antonijevic Irina
C/O BIOHAVEN LTD.
215 CHURCH STREET
NEW HAVEN
CT
06510
true
false
false
false
false
Common Shares
2023-12-29
4
M
false
11000.00
0.00
A
13535.00
D
Common Shares
2023-12-29
4
S
false
11000.00
41.7875
D
2535.00
D
Stock Options (Right to Buy)
7.00
2023-12-29
4
M
false
11000.00
0.00
D
2032-10-03
Common Shares
11000.00
114000.00
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.74 - $41.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
/s/ George Clark, Attorney-in-Fact
2023-12-29